NVG-444
/ Novalgen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 27, 2025
Preclinical development of NVG-444, a first-in-class next-generation FVIII mimetic antibody with Autoregulation for improved efficacy and safety
(EAHAD 2025)
- No abstract available
Preclinical
1 to 1
Of
1
Go to page
1